Quantitative Clinical Pharmacology
Daiichi Sankyo
Mark (Minseok) Lee, Pharm.D., M.S., is an up and coming scientist in the clinical pharmacology field with 7 years of experience in the pharmaceutical industry. His primary research interests are in oncology drug development, PK/PD modeling and simulation, and therapeutic optimization of innovative new medicines using a model-informed drug development (MIDD) approach. His work focuses on the application of these research interests to the development of antibody-drug conjugates (ADCs) in various tumor types. Mark holds a Pharm.D. from the University of Maryland, Baltimore (UMB), and an M.S. in Pharmacometrics, also from UMB. In 2020, Mark completed his post-doctoral fellowship in quantitative clinical pharmacology (QCP) at Daiichi Sankyo Inc. (DSI), where he continues to support the development of life-saving medicines for cancer patients.